Loading...
•
Jun 30, 2021
Scholar Rock Q2 2021 Earnings Report
Scholar Rock reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Scholar Rock reported a net loss of $30.7 million, or $0.84 per share, and revenue of $4.6 million for the quarter ended June 30, 2021. The company's cash and cash equivalents totaled approximately $282 million at the end of the quarter.
Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA) anticipated to initiate by end of 2021.
DRAGON Phase 1 trial evaluating SRK-181’s ability to overcome resistance to checkpoint inhibitors continues to progress and on-track to advance to Part B dose expansion mid-year 2021
Positive top-line data from the TOPAZ Phase 2 trial were presented, showing meaningful motor function improvements with apitegromab in SMA patients.
The FDA granted Fast Track designation for apitegromab for the treatment of patients with Spinal Muscular Atrophy.
Forward Guidance
Scholar Rock is working closely with regulatory authorities to finalize the design of the Phase 3 trial for apitegromab and to progress the DRAGON trial to Part B to evaluate SRK-181 across multiple tumor types.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...